Cipher Pharmaceuticals

230 articles with Cipher Pharmaceuticals

• Cipher Pharmaceuticals Reports Voting Results for the Election of Directors - Oct 09, 2020

  10/9/2020

  Cipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier.

• Cipher Pharmaceuticals Announces Normal Course Issuer Bid

  8/12/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, a Notice of Intention to Make a Normal Course Issuer Bid (the "Notice").

• Cipher Pharmaceuticals Reports Second Quarter 2020 Financial Results

  8/12/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six months ended June 30, 2020

• Cipher Pharmaceuticals Schedules Q2 2020 Earnings Release and Conference Call

  7/27/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2020 financial results after the close on Wednesday, August 12, 2020. 

• Cipher Pharmaceuticals Appoints New Chief Financial Officer

  7/2/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) (" Cipher " or " the Company ") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer (CFO), he will succeed Interim CFO Nadine Jutlah . Mr. Langille brings with him an extensive background in corporate and oper

• Cipher Pharmaceuticals Reports First Quarter 2020 Financial Results

  5/7/2020

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31, 2020.

• Cipher Pharmaceuticals Schedules Q1 2020 Earnings Release and Conference Call

  4/28/2020

  Cipher Pharmaceuticals Inc. announced it will release its Q1 2020 financial results on Thursday, May 7, 2020. The company will hold a conference call on Friday, May 8, 2020 to discuss the results.

• Cipher Pharmaceuticals Receives Positive Ruling on Binding Arbitration with Upsher-Smith Laboratories

  4/20/2020

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the Company has been successful in its binding arbitration with Upsher-Smith Laboratories LLC ("Upsher-Smith").

• Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

  3/25/2020

  Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter

• Notice of Cipher Pharmaceuticals Q4 2019 Conference Call

  2/20/2020

  OAKVILLE, ON , Feb. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2020 financial results conference call on Thursday, March 26, 2019 . CONFERENCE CALL DETAILS DATE:             Thursday, March 26, 2020 TIME:               8:30 a.m.

• Cipher Pharmaceuticals Provides Update on Absorica Brand Extension Program with Sun Pharmaceutical

  2/6/2020

  Cipher Pharmaceuticals Inc. is pleased to announce that Sun Pharmaceutical Industries Ltd., the Company's U.S. marketing partner for Absorica®, has launched ABSORICA LD™ capsules in the U.S for the management of severe recalcitrant nodular acne in patients 12 years of age and older.

• Cipher Pharmaceuticals Receives Notice of Termination from Bausch

  1/20/2020

  Cipher Pharmaceuticals Inc. announced the Company received a Notice of Termination from Bausch Health in connection with the License, Development and Commercialization Agreement of Trulance®.

• Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results

  11/7/2019

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and nine months ended September 30, 2019. Unless otherwise noted, all figures are in U.S. dollars..

• Notice of Cipher Pharmaceuticals Q3 2019 Conference Call

  10/24/2019

  Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America.

• Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)

  10/18/2019

  Cipher Pharmaceuticals Inc. announced it has received Health Canada approval, on October 10, 2019, for TRULANCE®, a Guanylate cyclase-C agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation.

• Cipher Pharmaceuticals Reports Second Quarter 2019 Financial Results

  8/9/2019

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three months ended June 30, 2019.

• Notice of Cipher Pharmaceuticals Q2 2019 Conference Call

  7/30/2019

  Cipher Pharmaceuticals Inc. announced the details of its Q2 2019 financial results conference call on Friday, August 9, 2019.

• Cipher Pharmaceuticals Announces Management Change & Preliminary Q2 Financial Highlights

  7/29/2019

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull has been named Interim Chief Executive Officer of Cipher, replacing Robert Tessarolo.

• Cipher Pharmaceuticals Reports Voting Results for the Election of Directors held on June 11, 2019

  6/12/2019

  Cipher Pharmaceuticals Inc., in accordance with Toronto Stock Exchange requirements, announced the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on June 11, 2019 in Toronto, Ontario.

• Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

  5/10/2019

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31st, 2019.